tbuckley/cabot-search huggingface dataset:
A Single Multiplex <scp>CytoBas</scp> Assay Incorporating Eight Major Components for Accurate Detection of Allergen Sensitization in Asthma and Allergic Rhinitis
Authors: Lin Hsin, Mark Hew, Pei Mun Aui, Kirsten Deckert, P. Mark Hogarth, Robyn E. O'Hehir, Menno C. van Zelm
Journal: Allergy (2025)

Allergic rhinitis and asthma can be triggered by a variety of aeroallergens, including house dust mites (HDM), tree and grass pollen, and household pets. Identification of the relevant allergen is critical for lifestyle changes and treatments, including allergen immunotherapy. We here assessed the diagnostic performance and clinical utility of a single flow cytometry staining of basophils with major aeroallergen components (AeroDiff CytoBas). In 156 atopic patients with allergic rhinitis/asthma and 21 non-atopic individuals, allergen-specific IgE levels were determined by ImmunoCAP, and component-specific IgE by ELISA. PBMCs were analyzed by flow cytometry with basophil markers and eight fluorochrome-conjugated allergen component tetramers. Patients were stratified for sensitization to each of the four allergens. Allergen-component staining in a single multiplex CytoBas assay and component-specific IgE serology performed similarly for Der p 2, Lol p 1, Fel d 1, and Can f 1 (ROC AUC: 0.76-0.97 vs. 0.73-0.93). CytoBas had greater diagnostic accuracy than component-specific IgE serology (p < 0.001) for HDM sensitization using Der f 1 or Der p 1, and grass pollen using Lol p 5 or Phl p 1. Furthermore, the combined evaluation of Der p 1 and Der p 2 with CytoBas was 96.3% sensitive and 90.7% specific for HDM sensitization. The combined evaluation of Lol p 1 and Lol p 5 achieved 95.4% sensitivity and 96.4% specificity for ryegrass pollen sensitization. AeroDiff CytoBas has similar to superior diagnostic accuracy compared to singleplex IgE serology, with the additional advantage of a single assay to evaluate multiple allergens. This enables precise and efficient component-resolved diagnosis of aeroallergen sensitization to guide personalized treatment for patients with allergic rhinitis and/or asthma.
Food Insecurity and Global Poverty—A Crisis for Trauma Patients
Authors: Vanessa P. Ho, Pooja Podugu, Marie L. Crandall
Journal: JAMA Surgery (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria
Authors: Aldo A. Acosta‐Medina, Meera Sridharan, Ronald S. Go, Ann M. Moyer, Nelson Leung, Maria Alice V. Willrich, Robert Wolf, Rabee Kassis, Almothana Manasrah, Mira A. Kohorst, Urshila Durani, Aasiya Matin, Mehrdad Hefazi, Saad J. Kenderian, Abhishek A. Mangaonkar, Mithun V. Shah, Mark R. Litzow, William J. Hogan, David Dingli, Hassan B. Alkhateeb
Journal: American Journal of Hematology (2025)

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high-risk features on the clinical outcomes of adult patients meeting the updated TA-TMA harmonizing criteria. Between 2005 and 2022, 99 patients were diagnosed with TA-TMA at Mayo Clinic Rochester (incidence 6.2%) after a median of 137 days post alloHCT (IQR: 34-283 days). The development of TA-TMA was associated with an inferior overall survival posttransplant (HR: 3.8, 95% CI: 2.97-4.72). High-risk features, including concomitant infection, acute graft-versus-host disease (GVHD), and organ dysfunction, were associated with poor survival, while LDH elevation was not associated with inferior outcomes. The most common treatment strategy for TA-TMA was discontinuation of calcineurin or mTOR inhibitors in 80 (81%) patients. Thirty (37.5%) patients experienced worsening of GVHD with this strategy, of which 26 (86.7%) patients had died at last follow-up. The most common cause of death among these patients was worsening GVHD (69%; n = 18), followed by infection (11%; n = 3), disease relapse (8%; n = 2), other/unknown causes (8%; n = 2), or TA-TMA (4%; n = 1). Objective response rate (ORR) to initial treatment for the cohort was 56.6%. Eculizumab was used in 11 patients with an observed ORR of 70%, including 5 complete responses. In conclusion, TA-TMA remains a significant contributor to non-relapse mortality and is associated with worse survival following alloHCT. Not all high-risk features, particularly LDH elevation, have consistently demonstrated a negative impact in adult cohorts. Patients with TA-TMA may benefit from immune suppression dose adjustment, rather than a discontinuation, and the addition of complement-directed therapy, particularly among high-risk patients.
Cholesterol‐27α‐hydroxylase inhibitor nilvadipine can effectively treat cholestatic liver injury in adult offspring induced by prenatal dexamethasone exposure
Authors: Wen Hu, Jiayong Zhu, Qi Zhang, Xiaoqian Lu, Luting Yu, Bin Li, Liaobin Chen, Hui Wang
Journal: MedComm (2025)

Prenatal dexamethasone exposure (PDE) can increase offspring susceptibility to various diseases. However, the pathogenesis and early prevention for PDE offspring prone to cholestatic liver injury have been unclear. In this study, we collected human umbilical cord blood from neonates with prenatal dexamethasone therapy, showing increased primary unconjugated bile acid levels in utero. PDE increased blood primary bile acid levels, enhanced endoplasmic reticulum stress, and led to cholestatic liver injury in adulthood in rats, which is accompanied by the persistent increase of H3K14ac level in cholesterol 27α-hydroxylase (CYP27A1) promoter and its expression before and after birth. In vitro, dexamethasone activates glucocorticoid receptors, binding to the CYP27A1 promoter, and promotes its transcriptional expression. Through the miR-450b-3p/SIRT1 pathway, it increased the H3K14ac level of the CYP27A1 promoter to enhance its transcription, which continues after birth. Finally, nilvadipine effectively reversed cholestatic liver injury induced by PDE. This study confirmed PDE could cause cholestatic liver injury, and innovatively proposed its early intervention target (CYP27A1) and effective drug (nilvadipine), providing a theoretical and experimental basis for guiding rational drug use during pregnancy, and preventing and treating the fetal-originated cholestatic liver injury.
Nanohybrid Hydrogel with Dual Functions: Controlled Low‐Temperature Photothermal Antibacterial Activity and Promoted Regeneration for Treating MRSA‐Infected Bone Defects
Authors: Fang Yang, Zewen Shi, Yiwei Hu, Qian Pang, Tianyu Du, Baiyang Song, Jiaqi Zhong, Xiaodong Hu, Weilai Zhu, Junhong Chen, Lin Shi, Xianjun Chen, Qingjiang Pang, Yabin Zhu
Journal: Advanced Healthcare Materials (2025)

Methicillin-resistant Staphylococcus aureus (MRSA)-related bone defects pose significant clinical challenges due to treatment failures. Here, an injectable nanohybrid hydrogel (FND-ZHD) is developed that combines controlled low-temperature photothermal antibacterial therapy with enhanced bone regeneration. The hydrogel uses Pluronic F-127 as the matrix, incorporating polydopamine-coated nano-hydroxyapatite and zinc oxide nanoparticles encapsulated with polydopamine and hyaluronic acid, forming a sophisticated nanostructured composite. Under near-infrared (NIR) irradiation, the FND-ZHD hydrogel exhibits efficient photothermal properties, enabling precise low-temperature photothermal therapy to eliminate MRSA infections. The photothermal process generates reactive oxygen species (ROS), contributing to potent antibacterial activity, while the hydrogel design allows self-elimination of excess ROS to minimize cytotoxicity. Simultaneously, the hydrogel enhances bone regeneration by upregulating heat shock protein 70 (HSP70), promoting osteogenic differentiation and accelerating bone repair. In vitro and in vivo experiments demonstrate that the FND-ZHD hydrogel not only possesses strong antibacterial efficacy against MRSA but also significantly improves bone healing in infected bone defect models. This dual-function strategy leverages the synergistic effects of nanomaterials at the nano- and microscale, achieving simultaneous antibacterial action and bone regeneration. The work highlights the potential of nanotechnology-based multifunctional biomaterials in addressing complex medical problems, paving the way for advanced therapies in orthopedic and regenerative medicine.
Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases
Authors: Carolina Roselli, Ida Surakka, Morten S Olesen, Gardar Sveinbjornsson, Nicholas A Marston, Seung Hoan Choi, Hilma Holm, Mark Chaffin, Daniel Gudbjartsson, Matthew C Hill, Hildur Aegisdottir, Christine M Albert, Alvaro Alonso, Christopher D Anderson, Dan E Arking, David O Arnar, John Barnard, Emelia J Benjamin, Eugene Braunwald, Ben Brumpton, Archie Campbell, Nathalie Chami, Daniel I Chasman, Kelly Cho, Eue-Keun Choi, Ingrid E Christophersen, Mina K Chung, David Conen, Harry J Crijns, Michael J Cutler, Tomasz Czuba, Scott M Damrauer, Martin Dichgans, Marcus Dörr, Elton Dudink, ThuyVy Duong, Christian Erikstrup, Tõnu Esko, Diane Fatkin, Jessica D Faul, Manuel Ferreira, Daniel F Freitag, Santhi K Ganesh, J Michael Gaziano, Bastiaan Geelhoed, Jonas Ghouse, Christian Gieger, Franco Giulianini, Sarah E Graham, Vilmundur Gudnason, Xiuqing Guo, Christopher Haggerty, Caroline Hayward, Susan R Heckbert, Kristian Hveem, Kaoru Ito, Renee Johnson, J Wouter Jukema, Sean J Jurgens, Stefan Kääb, John P Kane, Shinwan Kany, Sharon L R Kardia, Maryam Kavousi, Shaan Khurshid, Frederick K Kamanu, Paulus Kirchhof, Marcus E Kleber, Stacey Knight, Issei Komuro, Jose E Krieger, Lenore J Launer, Dadong Li, Honghuang Lin, Henry J Lin, Ruth J F Loos, Luca Lotta, Steven A Lubitz, Kathryn L Lunetta, Peter W Macfarlane, Patrik K E Magnusson, Rainer Malik, Helene Mantineo, Gregory M Marcus, Winfried März, David D McManus, Olle Melander, Giorgio E M Melloni, Pascal B Meyre, Kazuo Miyazawa, Sanghamitra Mohanty, Laia M Monfort, Martina Müller-Nurasyid, Navid A Nafissi, Andrea Natale, Saman Nazarian, Sisse R Ostrowski, Hui-Nam Pak, Shichao Pang, Ole B Pedersen, Nancy L Pedersen, Alexandre C Pereira, James P Pirruccello, Michael Preuss, Bruce M Psaty, Clive R Pullinger, Daniel J Rader, Joel T Rämö, Paul M Ridker, Michiel Rienstra, Lorenz Risch, Dan M Roden, Jerome I Rotter, Marc S Sabatine, Heribert Schunkert, Svati H Shah, Jaemin Shim, M Benjamin Shoemaker, Bridget Simonson, Moritz F Sinner, Roelof A J Smit, Jennifer A Smith, Nicholas L Smith, J Gustav Smith, Elsayed Z Soliman, Erik Sørensen, Nona Sotoodehnia, Daniel Strbian, Bruno H Stricker, Maris Teder-Laving, Yan V Sun, Sébastien Thériault, Rosa B Thorolfsdottir, Unnur Thorsteinsdottir, Arnljot Tveit, Pim van der Harst, Joyce van Meurs, Biqi Wang, Stefan Weiss, Quinn S Wells, Lu-Chen Weng, Peter W Wilson, Ling Xiao, Pil-Sung Yang, Jie Yao, Zachary T Yoneda, Tanja Zeller, Lingyao Zeng, Wei Zhao, Xiang Zhou, Sebastian Zöllner, Christian T Ruff, Henning Bundgaard, Cristen Willer, Kari Stefansson, Patrick T Ellinor
Journal: Nature Genetics (2025)
Against Medical Advice: Counternarrative Poetry and Medicine
Authors: Rafael Campo
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute lower‐limb heating improves exercise performance in individuals with heart failure with reduced ejection fraction
Authors: Fergus K. O'Connor, Surendran Sabapathy, Pramod Sharma, Llion Roberts, James R. Walsh, Aaron J.E. Bach, Alon G.M. Hopman, Menaka Louis, Bryce N. Balmain, Norman R. Morris
Journal: European Journal of Heart Failure (2025)
18F-FDG PET/CT Identified Rectal Malignancy Earlier Than 68Ga-FAPI PET/CT
Authors: Hui Wang, Minggang Su
Journal: Clinical Nuclear Medicine (2025)

A 69-year-old man with esophageal cancer underwent dual-tracer PET/CT using 18F-FDG and 68Ga-FAPI during his treatment. At baseline, neither scan showed abnormal uptake in the rectum. Three months later, an interim 18F-FDG PET/CT revealed focal uptake in the rectum, while the 68Ga-FAPI PET/CT showed no abnormal findings. Seventeen months later, he received a third dual-tracer PET/CT for surveillance. Both 18F-FDG and 68Ga-FAPI PET/CT detected abnormal activity in the same area of the rectum​​​​​​. The lesion was later confirmed as adenocarcinoma by histopathology after surgery. Our case demonstrated the 18F-FDG PET/CT could identify the rectal malignancy before 68Ga-FAPI PET/CT.
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression
Authors: Matheus Rassi F. Ramos, Stephan Goerigk, Valquiria Aparecida da Silva, Beatriz Araújo Cavendish, Bianca Silva Pinto, Cássio Henrique Gomide Papa, João Vitor Resende, Izio Klein, Adriana Munhoz Carneiro, Juliana Pereira de Sousa, Kallene Summer Moreira Vidal, Leandro da Costa Lane Valiengo, Lais B. Razza, Luana Marotti Aparício, Lisiane Martins, Lucas Borrione, Mariana Batista, Natasha Kouvalesk Moran, Leonardo Afonso dos Santos, Rafael Benatti, Rebeca Pelosof, Frank Padberg, Andre R. Brunoni
Journal: JAMA Psychiatry (2025)

Intermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting. To evaluate the efficacy and safety of a pragmatic aTBS protocol for TRD. This triple-blinded, sham-controlled randomized clinical trial was conducted at a single center in São Paulo, Brazil, from July 2022 to June 2024, with a subsequent open-label phase. Patients aged 18 to 65 years with major depression, experiencing a TRD episode, and with a Hamilton Depression Rating Scale, 17-item (HDRS-17) score of 17 or higher were eligible for inclusion. Exclusion criteria were other psychiatric disorders (except anxiety), neurological conditions, and TBS contraindications. Participants received 45 active or sham stimulation sessions over 15 weekdays, with 3 iTBS sessions (1200 pulses each) per day, spaced 30 minutes apart and targeting the left dorsolateral prefrontal cortex using a craniometric approach. In the open-label phase, additional aTBS sessions were offered to achieve a response (≥50% HDRS-17 score improvement) if needed. The primary outcome was change in HDRS-17 score at week 5. Of 431 volunteers screened, 100 participants were enrolled and randomized to either sham or active aTBS. Mean (SD) participant age was 41.7 (8.8) years, and 84 participants (84%) were female. A total of 89 patients completed the study. In the intention-to-treat analysis, the mean change in HDRS-17 scores from baseline to the study end point was 5.57 (95% CI, 3.99-7.16) in the sham group and 9.68 (95% CI, 8.11-11.25) in the active group, corresponding to 31.87% and 54.7% score reductions, respectively, and a medium-to-large effect size (Cohen d, 0.65; 95% CI, 0.29-1.00; P < .001). Response and remission rates were also higher in the active group. Both interventions were well tolerated, but scalp pain was more frequent in the active group than the sham group (17.4% vs 4.4%). During the open-label phase, approximately 75% of patients received additional sessions. In this triple-blinded, sham-controlled randomized clinical trial, a pragmatic aTBS protocol using only 3 iTBS sessions per day and a nonexpensive, non-neuronavigated approach was found to be safe and effective for TRD. ClinicalTrials.gov Identifier: NCT05388539.
Non‐Allergic Urticarial Skin Reactions Associated With <scp>MOv18 IgE</scp>, a First‐In‐Class <scp>IgE</scp> Antibody Recognising Folate Receptor Alpha
Authors: Chara Stavraka, Jitesh Chauhan, Silvia Crescioli, Sheila M. McSweeney, Amy Pope, Cheryl Gillett, Ashley Di Meo, Ioannis Prassas, Roman Laddach, Katie Stoker, Alexandra J. McCraw, Rebecca Adams, Thomas J. Tull, Nabeel Naban, Zena Willsmore, Kristina V. Semkova, Clive E. H. Grattan, John McGrath, Stephen J. Till, Christopher J. Corrigan, Rebecca Kristeleit, Sophia Tsoka, Eleftherios P. Diamandis, Katie E. Lacy, Sarah Pinder, Debra H. Josephs, James Spicer, Heather J. Bax, Sophia N. Karagiannis
Journal: Allergy (2025)

IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients. Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-lesional skin biopsies from a patient who developed an urticarial skin reaction. Systemic immunological markers including cytokines, β-tryptase and basophil activation states were interrogated throughout the trial and contemporaneously with the skin reaction. Of the 24 IgE-treated patients, 62.5% developed transient urticarial skin reactions, with onset during the first infusion, diminishing with consecutive infusions and no β-tryptase elevation nor clinical features indicating allergic aetiology. No FRα expression or MOv18 IgE binding to human skin was identified. Lesional skin biopsies from a patient given the highest antibody dose revealed scattered eosinophils, neutrophils and mast cell degranulation, but no increased immune cell infiltration. Transcriptomic analysis indicated pro-inflammatory, but not allergic, pathway activation. No systemic allergic or hypersensitivity mediators or basophil activation were detected. Urticarial skin reactions following MOv18 IgE treatment were unlikely to result from allergic mechanisms or skin antigen recognition. The clinical presentation is consistent with infusion-related reactions commonly observed with monoclonal antibody treatments. EudraCT number: 2014-000070-19; ClinicalTrials.gov identifier: NCT02546921, registered 11/Sept/2015.
Simulated Microplastic Release from Cutting Boards and Evaluation of Intestinal Inflammation and Gut Microbiota in Mice
Authors: Hai-Jun Gan, Shan Chen, Ke Yao, Xin-Ying Lin, Albert L. Juhasz, Dongmei Zhou, Hong-Bo Li
Journal: Environmental Health Perspectives (2025)

Plastic cutting boards are commonly used in food preparation, increasing human exposure to microplastics (MPs). However, the health implications are still not well understood. The objective of this study was to assess the impacts of long-term exposure to MPs released from cutting boards on intestinal inflammation and gut microbiota. MPs were incorporated into mouse diets by cutting the food on polypropylene, polyethylene, and willow wooden cutting boards; diets were fed to mice over periods of 4 and 12 weeks. Serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), lipopolysaccharide (LPS, an endotoxin), and carcinoembryonic antigen (CEA), along with ileum and colon levels of IL-1β, TNF-α, malondialdehyde (MDA), superoxide dismutase (SOD), secretory immunoglobulin A (sIgA), and myosin light chain kinase (MLCK), were measured using mouse ELISA kits. The mRNA expression of mucin 2 and intestinal tight junction proteins in mouse ileum and colon tissues was quantified using real-time quantitative RT-PCR. Fecal microbiota, fecal metabolomics, and liver metabolomics were characterized. Polypropylene and polyethylene cutting boards released MPs, with concentrations reaching 1088 ± 95.0 and 1211 ± 322 µg g-1 in diets, respectively, and displaying mean particle sizes of 10.4 ± 0.96 vs 27.4 ± 1.45 µm. Mice fed diets prepared on polypropylene cutting boards for 12 weeks exhibited significantly higher serum levels of LPS, CRP, TNF-α, IL-10, and CEA, as well as higher levels of IL-β, TNF-α, MDA, SOD, and MLCK in the ileum and colon compared to mice fed diets prepared on willow wooden cutting boards. These mice also showed lower relative expression of Occludin and Zonula occludens-1 in the ileum and colon. In contrast, mice exposed to diets prepared on polyethylene cutting boards for 12 weeks did not show evident inflammation; however, there was a significant decrease in the relative abundance of Firmicutes and an increase in Desulfobacterota compared to those fed diets prepared on willow wooden cutting boards, while exposure to diets prepared on polyethylene cutting boards over 12 weeks also altered mouse fecal and liver metabolites compared to those fed diets prepared on willow wooden cutting boards. The findings suggest that MPs from polypropylene cutting boards impaired intestinal barrier function and induced inflammation, whereas those from polyethylene cutting boards affected the gut microbiota, gut metabolism, and liver metabolism in the mouse model. These findings offer crucial insights into the safe use of plastic cutting boards. https://doi.org/10.1289/EHP15472.